Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Shares Outstanding (Weighted Average): 2013-2025

Historic Shares Outstanding (Weighted Average) for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $21.4 million.

  • Enanta Pharmaceuticals' Shares Outstanding (Weighted Average) rose 0.89% to $21.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.4 million, marking a year-over-year increase of 0.89%. This contributed to the annual value of $21.4 million for FY2025, which is 0.89% up from last year.
  • According to the latest figures from FY2025, Enanta Pharmaceuticals' Shares Outstanding (Weighted Average) is $21.4 million, which was up 0.89% from $21.2 million recorded in FY2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $21.4 million during FY2025, and registered a low of $20.2 million during FY2021.
  • Over the past 3 years, Enanta Pharmaceuticals' median Shares Outstanding (Weighted Average) value was $21.2 million (recorded in 2024), while the average stood at $21.2 million.
  • Data for Enanta Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY grew of 2.52% (in 2022) over the last 5 years.
  • Enanta Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $20.2 million in 2021, then grew by 2.52% to $20.7 million in 2022, then grew by 1.59% to $21.1 million in 2023, then climbed by 0.63% to $21.2 million in 2024, then grew by 0.89% to $21.4 million in 2025.